ECTS2013 Poster Presentations Osteoporosis: treatment (64 abstracts)
Early response to once-monthly oral minodronate after switching from daily or weekly bisphosphonates in Japanese osteoporotic patients
Akinori Sakai 1 , Satoshi Ikeda 2 , Nobukazu Okimoto 3, , Kitau Teshima 5 , Shinobu Arita 6 , Hidehiro Matsumoto 7 , Hiroshi Tsurukami 8 , Yuichi Okazaki 9 , Masato Nagashima 10 , Fumio Fukuda 11 & Toru Yoshioka 12
1University of Occupational and Environmental Health, Kitakyushu, Japan; 2Ken-Ai Memorial Hospital, Onga, Japan; 3Okimoto Clinic, Kure, Japan; 4Okamoto Orthopaedics and Sports Clinic, Hiroshima, Japan; 5Teshima Orthopaedic Clinic, Kitakyushu, Japan; 6Obase Hospital, Kanda, Miyako, Japan; 7Sanzai Hospital, Saito, Japan; 8Tsurukami Orthopaedic and Rheumatoid Clinic, Tamana, Japan; 9Makiyama Central Hospital, Kitakyushu, Japan; 10Katsuki Neurosurgery and Orthopaedic Clinic, Nogata, Japan; 11Kitakyushu General Hospital, Kitakyushu, Japan; 12Saka Midorii Hospital, Hiroshima, Japan.
Introduction: Minodronate, a highly potent, new-generation bisphosphonate (BP), is the first BP available as a once-monthly oral regimen in Japan. The aim of the present study was to investigate the effects of once-monthly oral minodronate on bone turnover markers (BTM) and bone mineral density (BMD) in osteoporotic patients previously using daily or weekly BPs in real clinical practice.
Methods: We conducted a prospective multicenter study involving 11 institutions in Japan. A total of 389 patients (367 females) using BPs for the treatment of osteoporosis were enrolled. Participants were divided into two groups depending on their preference for dosing regimens as follows: MIN50 mg group (n=258) were switched to once-monthly minodronate (50 mg), and d/wBP group (n=131) continued their current daily or weekly BP. Serum TRACP-5b was measured at baseline and 1, 2 and 6 months post-treatment. Serum P1NP was measured at baseline and 2 and 6 months post-treatment. BMD of lumbar spine, total hip, and/or 1/3 distal radius were measured at baseline and 6 months post-treatment.
Results: In MIN50 mg group, significant reductions were seen in TRACP-5b at 1 month post-treatment (−10.3%, P<0.01) and onward, and in P1NP at 2 months post-treatment (−8.0%, P<0.01) and onward, while remaining within the reference range for a healthy young adult. BMD in the MIN50 mg group was significantly increased at lumbar (+1.4%, P<0.001) and radius (+1.1%, P<0.01) at 6 months after therapy; however no significant changes were seen in the d/wBP group.
Conclusion: Once-monthly minodronte after switched from daily or weekly BPs demonstrated prompt BTM suppression within the normal reference range and superior BMD gains compared with continuing previous BPs. Thus, once-monthly minodronate provides an effective and convenient alternative to current BP therapies.
Article tools
My recent searches
My recently viewed abstracts
Authors
Bone Abstracts
ISSN 2052-1219 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more